{"transactions":[{"id":1829897,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-14T20:00:39.000Z","date":"2023-07-13","kind":"sale","planned":false,"acquired":false,"shares":5344,"price":0.7,"value":3740.8,"ownership":{"direct":true},"balance_after":8871747,"source":{"system":"sec-edgar","filing":"0000950170-23-032986","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000095017023032986/ownership.xml","form_type":"4"}},{"id":1829896,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-14T20:00:39.000Z","date":"2023-07-12","kind":"sale","planned":false,"acquired":false,"shares":80528,"price":0.7082,"value":57029.9296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8877091,"source":{"system":"sec-edgar","filing":"0000950170-23-032986","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000095017023032986/ownership.xml","form_type":"4"}},{"id":1844703,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-26T20:46:19.000Z","date":"2023-06-23","kind":"sale","planned":false,"acquired":false,"shares":18100,"price":0.7036,"value":12735.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.716. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8957619,"source":{"system":"sec-edgar","filing":"0000899243-23-016491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000089924323016491/doc4.xml","form_type":"4"}},{"id":1844702,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-26T20:46:19.000Z","date":"2023-06-22","kind":"sale","planned":false,"acquired":false,"shares":10508,"price":0.7027,"value":7383.9716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.7185. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8975719,"source":{"system":"sec-edgar","filing":"0000899243-23-016491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000089924323016491/doc4.xml","form_type":"4"}},{"id":1847246,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:00:11.000Z","date":"2023-06-21","kind":"sale","planned":false,"acquired":false,"shares":138962,"price":0.7026,"value":97634.7012,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.719. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8986227,"source":{"system":"sec-edgar","filing":"0000899243-23-016232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000089924323016232/doc4.xml","form_type":"4"}},{"id":1847245,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:00:11.000Z","date":"2023-06-20","kind":"sale","planned":false,"acquired":false,"shares":295653,"price":0.711,"value":210209.283,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.78. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9125189,"source":{"system":"sec-edgar","filing":"0000899243-23-016232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000089924323016232/doc4.xml","form_type":"4"}},{"id":1964415,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-09T00:38:47.000Z","date":"2023-03-06","kind":"disposition_to_issuer","acquired":false,"shares":199500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This option was canceled by mutual agreement of the Issuer and the Reporting Person. The Reporting Person received the RSU Award in exchange for the cancellation of this option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Prior to the cancellation of this option, 25% of the total number of shares underlying the option were to vest and become exercisable on November 10, 2023 and the remainder were to vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.95,"expiration_date":"2032-11-10","underlying":"Common Stock","underlying_shares":199500},"source":{"system":"sec-edgar","filing":"0001209191-23-017342","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123017342/doc4.xml","form_type":"4"}},{"id":1964414,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T00:38:47.000Z","date":"2023-03-06","kind":"other","acquired":true,"shares":251296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Reporting Person's annual incentive compensation for 2021 performance awarded in the discretion of the compensation committee of the Issuer's board of directors (the \"RSU Award\"). The RSU Award replaced a prior stock option award of 199,500 shares of similar value that was canceled effective March 6, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each share is represented by an RSU. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs are fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In connection with the Reporting Person's separation from the Issuer, the Reporting Person forfeited 21,374 unvested shares pursuant to a restricted stock award."}],"balance_after":9420842,"source":{"system":"sec-edgar","filing":"0001209191-23-017342","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123017342/doc4.xml","form_type":"4"}},{"id":2077210,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-12-23T21:15:43.000Z","date":"2022-11-10","kind":"grant","acquired":true,"shares":199500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents Reporting Person's annual incentive compensation for 2021 performance awarded in the discretion of the compensation committee of the Issuer's board of directors on November 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on November 10, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":199500,"derivative":{"exercise_price":1.95,"expiration_date":"2032-11-10","underlying":"Common Stock","underlying_shares":199500},"source":{"system":"sec-edgar","filing":"0001209191-22-062615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122062615/doc4.xml","form_type":"4"}},{"id":2373347,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-25T21:17:06.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":217850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":217850,"derivative":{"exercise_price":5.96,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":217850},"source":{"system":"sec-edgar","filing":"0001209191-22-013156","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122013156/doc4.xml","form_type":"4"}},{"id":2481365,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-12-08T21:05:35.000Z","date":"2021-11-23","kind":"purchase","acquired":true,"shares":26008,"price":12.65,"value":329001.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.46 to $12.94 inclusive."}],"balance_after":9190920,"source":{"system":"sec-edgar","filing":"0001209191-21-068510","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121068510/doc4.xml","form_type":"4"}},{"id":2481364,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-12-08T21:05:35.000Z","date":"2021-11-23","kind":"purchase","acquired":true,"shares":16510,"price":12.12,"value":200101.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.46 to $12.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2)."}],"balance_after":9164912,"source":{"system":"sec-edgar","filing":"0001209191-21-068510","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121068510/doc4.xml","form_type":"4"}},{"id":2903492,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-21T01:22:57.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":199700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":199700,"derivative":{"exercise_price":31,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":199700},"source":{"system":"sec-edgar","filing":"0001209191-21-004573","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121004573/doc4.xml","form_type":"4"}},{"id":3933000,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Corp Strategy"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:39:34.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":6572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":6572},"source":{"system":"sec-edgar","filing":"0001209191-18-030129","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030129/doc4.xml","form_type":"4"}},{"id":3932999,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Corp Strategy"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:39:34.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":1282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":77.24,"expiration_date":"2027-05-10","underlying":"Common Stock","underlying_shares":1282},"source":{"system":"sec-edgar","filing":"0001209191-18-030129","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030129/doc4.xml","form_type":"4"}},{"id":3932998,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Corp Strategy"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:39:34.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":35950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":79.75,"expiration_date":"2027-03-20","underlying":"Common Stock","underlying_shares":35950},"source":{"system":"sec-edgar","filing":"0001209191-18-030129","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030129/doc4.xml","form_type":"4"}},{"id":3932997,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Corp Strategy"}}],"security":"Common Stock","published_at":"2018-05-15T12:39:34.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 1,667 shares underlying Restricted Stock Units (the \"RSUs\"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-030129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030129/doc4.xml","form_type":"4"}},{"id":3981979,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Corp Strategy"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-27T17:34:05.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":6572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable as to 25% of the shares underlying the option on March 13, 2019; the remaining shares shall vest in 36 equal monthly installments beginning on April 13, 2019, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":6572,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":6572},"source":{"system":"sec-edgar","filing":"0001209191-18-021795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118021795/doc4.xml","form_type":"4"}},{"id":3981978,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Corp Strategy"}}],"security":"Common Stock","published_at":"2018-03-27T17:34:05.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":1667,"source":{"system":"sec-edgar","filing":"0001209191-18-021795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118021795/doc4.xml","form_type":"4"}},{"id":4322806,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Corp Strategy"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-05-12T18:34:33.000Z","date":"2017-05-10","kind":"grant","acquired":true,"shares":1282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable as to 25% of the shares underlying the option on May 10, 2018; the remaining shares shall vest in 36 equal monthly installments beginning on June 10, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":1282,"derivative":{"exercise_price":77.24,"expiration_date":"2027-05-10","underlying":"Common Stock","underlying_shares":1282},"source":{"system":"sec-edgar","filing":"0001209191-17-032156","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117032156/doc4.xml","form_type":"4"}},{"id":4373650,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":111407,"kind":"person","name":"Session R.A. II","position":1,"cik":"0001701846","reported_name":"Session R.A. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Corp Strategy"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-03-23T16:21:20.000Z","date":"2017-03-20","kind":"grant","acquired":true,"shares":35950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable as to 8,987 shares on March 20, 2018; and the remainder shall vest and become exercisable in 36 equal installments on the last day of each calendar month, in each case subject to the Reporting Person's Continuous Service (as that term is defined in the Plan) through each such date."}],"balance_after":35950,"derivative":{"exercise_price":79.75,"expiration_date":"2027-03-20","underlying":"Common Stock","underlying_shares":35950},"source":{"system":"sec-edgar","filing":"0001209191-17-022565","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117022565/doc4.xml","form_type":"4"}}]}